The overall goal of this collaborative project is to develop CDK5 as a therapeutic target in pancreatic cancer. This project is based on our preliminary data, showing that CDK5 inhibition in pancreatic cancer cell lines reduced their migration and invasion in vitro, and their tumor growth and metastasis in vivo. In addition, we have found that inhibition of CDK5 in pancreatic cancer cells inhibits signal transduction pathways that are activated by ras. This suggests that CDK5 inhibition may antagonize the ras pathway in pancreatic cancer. Since ras mutation or dysregulation is present in the vast majority of pancreatic adenocarcinomas, this is a possibility of considerable potential therapeutic significance. A genetically engineered animal model for the role of CDK5 in pancreatic tumorigenesis and metastasis will be developed, based on pancreas specific ablation of the Cdk5 gene in the well characterized Pdx1-cre K-ras?G12D p53?R172H model of pancreatic cancer (Hingorani et al, 2005). The effect of CDK5 inhibition on downstream ras-mediated signaling pathways in pancreatic cancer cells, including RalA, RalB, MEK/ERK, PI3-K and Hedgehog, will be examined. The potential that CDK5 affects oncogenic signal transduction through a linear pathway from RalA, through effectors src and STAT3, will be explored. The potential that blocking these CDK5-mediated pathways may induce sensitivity to chemotherapeutic agents will be examined. The ability of CDK5 to induce or augment aspects of neoplastic transformation in pancreatic epithelial cells will be investigated. A selective CDK5 inhibitor will be evaluated for its potential therapeutic efficacy in an in vivo preclinical platform of human pancreatic adenocarcinoma. The effect of combination therapy, using this CDK5 inhibitor with standard gemcitabine or other chemotherapeutic agents, will be explored.
Our preliminary data indicate that inhibition of CDK5 can limit growth and metastasis of pancreatic cancer. In the current project, we will develop CDK5 as a potential therapeutic target for the control of pancreatic cancer.
|Hu, Chaoxin; Dadon, Tikva; Chenna, Venugopal et al. (2015) Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models. Mol Cancer Ther 14:1532-9|
|Wissing, Michel D; Dadon, Tikva; Kim, Eunice et al. (2014) Small-molecule screening of PC3 prostate cancer cells identifies tilorone dihydrochloride to selectively inhibit cell growth based on cyclin-dependent kinase 5 expression. Oncol Rep 32:419-24|
|Le, Anne; Rajeshkumar, N V; Maitra, Anirban et al. (2012) Conceptual framework for cutting the pancreatic cancer fuel supply. Clin Cancer Res 18:4285-90|
|Penchev, Vesselin R; Rasheed, Zeshaan A; Maitra, Anirban et al. (2012) Heterogeneity and targeting of pancreatic cancer stem cells. Clin Cancer Res 18:4277-84|
|Cardoso, Angelo A; Jiang, Yanlin; Luo, Meihua et al. (2012) APE1/Ref-1 regulates STAT3 transcriptional activity and APE1/Ref-1-STAT3 dual-targeting effectively inhibits pancreatic cancer cell survival. PLoS One 7:e47462|
|Fishel, Melissa L; Jiang, Yanlin; Rajeshkumar, N V et al. (2011) Impact of APE1/Ref-1 redox inhibition on pancreatic tumor growth. Mol Cancer Ther 10:1698-708|
|Feldmann, Georg; Mishra, Anjali; Bisht, Savita et al. (2011) Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Cancer Biol Ther 12:598-609|
|Feldmann, Georg; Karikari, Collins; dal Molin, Marco et al. (2011) Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Cancer Biol Ther 11:959-68|
|Bisht, Savita; Khan, Mehtab A; Bekhit, Mena et al. (2011) A polymeric nanoparticle formulation of curcumin (NanoCurc™) ameliorates CCl4-induced hepatic injury and fibrosis through reduction of pro-inflammatory cytokines and stellate cell activation. Lab Invest 91:1383-95|
|Von Hoff, Daniel D; Ramanathan, Ramesh K; Borad, Mitesh J et al. (2011) Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol 29:4548-54|
Showing the most recent 10 out of 14 publications